DBV Technologies S.A. (DBVT): Price and Financial Metrics
GET POWR RATINGS... FREE!
DBVT POWR Grades
- DBVT scores best on the Stability dimension, with a Stability rank ahead of 60.33% of US stocks.
- DBVT's strongest trending metric is Sentiment; it's been moving down over the last 72 days.
- DBVT ranks lowest in Momentum; there it ranks in the 18th percentile.
DBVT Stock Summary
- With a one year PEG ratio of 0.47, DBV TECHNOLOGIES SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- With a price/sales ratio of 27.33, DBV TECHNOLOGIES SA has a higher such ratio than 94.96% of stocks in our set.
- With a year-over-year growth in debt of -75.93%, DBV TECHNOLOGIES SA's debt growth rate surpasses just 2.82% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to DBV TECHNOLOGIES SA are SONN, VCNX, CANF, HYLN, and IPSC.
- DBVT's SEC filings can be seen here. And to visit DBV TECHNOLOGIES SA's official web site, go to www.dbv-technologies.com.
DBVT Valuation Summary
- DBVT's price/earnings ratio is -3.9; this is 117.18% lower than that of the median Healthcare stock.
- DBVT's price/sales ratio has moved down 167 over the prior 100 months.
Below are key valuation metrics over time for DBVT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DBVT | 2023-01-20 | 30.2 | 1.3 | -3.9 | -0.9 |
| DBVT | 2023-01-19 | 30.9 | 1.3 | -4.0 | -1.0 |
| DBVT | 2023-01-18 | 30.9 | 1.3 | -4.0 | -1.0 |
| DBVT | 2023-01-17 | 31.7 | 1.4 | -4.1 | -1.1 |
| DBVT | 2023-01-13 | 32.3 | 1.4 | -4.1 | -1.2 |
| DBVT | 2023-01-12 | 31.3 | 1.3 | -4.0 | -1.0 |
DBVT Stock Price Chart Interactive Chart >
DBVT Price/Volume Stats
| Current price | $1.32 | 52-week high | $3.43 |
| Prev. close | $1.35 | 52-week low | $1.08 |
| Day low | $1.32 | Volume | 65,130 |
| Day high | $1.39 | Avg. volume | 157,077 |
| 50-day MA | $1.40 | Dividend yield | N/A |
| 200-day MA | $1.80 | Market Cap | 248.52M |
DBV Technologies S.A. (DBVT) Company Bio
DBV Technologies SA has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. The company was founded in 2002 and is based in Bagneux, France.
Latest DBVT News From Around the Web
Below are the latest news stories about DBV TECHNOLOGIES SA that investors may wish to consider to help them evaluate DBVT as an investment opportunity.
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFAMF Regulated InformationMontrouge, France, January 23, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31, 2022: 149,793 DBV Tec |
Results from DBV Technologies S.A. (DBVT) show potentialDBV Technologies S.A. (NASDAQ:DBVT) closed Monday at $1.56 per share, up from $1.54 a day earlier. While DBV Technologies S.A. has overperformed by 1.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DBVT fell by -7.69%, with highs and lows ranging from $3.43 to $1.08, whereas […] |
DBV Technologies S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Mar… |
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market: NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of sharesTotal number of voting rights12/31/202294,137,145Total gross of voting rights: 94,137,145Total net* of voting rights: 93,966,891 * Total net = total number of voting rights attached to shares – shares withou |
DBV Tech Rises after FDA Lifts Hold on Phase 3 TrialShares of biopharmaceutical company DBV Technologies (NASDAQ:DBVT) are rising today after the U.S. Food and Drug Administration lifted the partial … |
DBVT Price Returns
| 1-mo | -13.73% |
| 3-mo | -10.20% |
| 6-mo | -48.03% |
| 1-year | -13.73% |
| 3-year | -86.43% |
| 5-year | -94.31% |
| YTD | -13.73% |
| 2022 | -4.38% |
| 2021 | -38.93% |
| 2020 | -75.51% |
| 2019 | 66.67% |
| 2018 | -73.90% |
Loading social stream, please wait...